CA2957868C - Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative - Google Patents

Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative Download PDF

Info

Publication number
CA2957868C
CA2957868C CA2957868A CA2957868A CA2957868C CA 2957868 C CA2957868 C CA 2957868C CA 2957868 A CA2957868 A CA 2957868A CA 2957868 A CA2957868 A CA 2957868A CA 2957868 C CA2957868 C CA 2957868C
Authority
CA
Canada
Prior art keywords
compound
rsv
formula
salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2957868A
Other languages
English (en)
French (fr)
Other versions
CA2957868A1 (en
Inventor
Simon Fraser Hunt
Stuart Thomas Onions
Vladimir Sherbukhin
Euan Alexander Fraser Fordyce
Peter John Murray
Daniel William BROOKES
Kazuhiro Ito
Peter Strong
Matthew Stephen COATES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of CA2957868A1 publication Critical patent/CA2957868A1/en
Application granted granted Critical
Publication of CA2957868C publication Critical patent/CA2957868C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA2957868A 2014-10-10 2015-10-08 Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative Active CA2957868C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
EP14188494.0 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (2)

Publication Number Publication Date
CA2957868A1 CA2957868A1 (en) 2016-04-14
CA2957868C true CA2957868C (en) 2023-02-28

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2957868A Active CA2957868C (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative

Country Status (13)

Country Link
US (6) US10189863B2 (en:Method)
EP (2) EP3204389B1 (en:Method)
JP (2) JP2017531039A (en:Method)
KR (1) KR20170058921A (en:Method)
CN (1) CN106852144B (en:Method)
AU (1) AU2015329789B2 (en:Method)
BR (1) BR112017005104B1 (en:Method)
CA (1) CA2957868C (en:Method)
EA (1) EA201790796A8 (en:Method)
IL (1) IL250823A0 (en:Method)
MX (1) MX2017004652A (en:Method)
SG (1) SG11201701184WA (en:Method)
WO (2) WO2016055791A1 (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106852144B (zh) * 2014-10-10 2019-08-30 普尔莫赛德有限公司 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物
US10160772B2 (en) 2014-12-18 2018-12-25 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
CN108200760B (zh) 2015-07-22 2022-04-01 英安塔制药有限公司 作为rsv抑制剂的苯并二氮杂䓬衍生物
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA202092250A1 (ru) * 2016-02-03 2020-12-11 Янссен Сайенсиз Айрлэнд Юси Комбинированные продукты для лечения rsv
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
ES2923521T3 (es) 2017-02-16 2022-09-28 Enanta Pharm Inc Procesos para la preparación de derivados de benzodiazepina
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
JP7198811B2 (ja) 2017-09-29 2023-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド Rsv阻害剤としての組み合わせ医薬剤
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019199908A1 (en) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CN113710276B (zh) 2019-03-18 2024-03-29 英安塔制药有限公司 苯二氮䓬衍生物作为rsv抑制剂
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) * 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
UY39642A (es) 2021-02-26 2022-09-30 Enanta Pharm Inc Compuestos heterocíclicos antivirales
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
AU2009204147A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8999969B2 (en) 2009-07-09 2015-04-07 Gilead Sciences, Inc. Anti-RSV compounds
US9144557B2 (en) 2009-10-13 2015-09-29 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
EA025611B1 (ru) 2010-07-29 2017-01-30 Райджел Фармасьютикалз, Инк. Активирующие ampk гетероциклические соединения и способы их использования
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
MX2017001587A (es) 2014-08-05 2017-10-11 Alios Biopharma Inc Terapia de combinacion para tratar un paramixovirus.
CN106852144B (zh) 2014-10-10 2019-08-30 普尔莫赛德有限公司 5,6-二氢-4H-苯并[b]噻吩并-[2,3-d]氮杂*衍生物
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA202092250A1 (ru) 2016-02-03 2020-12-11 Янссен Сайенсиз Айрлэнд Юси Комбинированные продукты для лечения rsv
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

Also Published As

Publication number Publication date
EP3204388B1 (en) 2018-12-12
MX2017004652A (es) 2017-06-19
BR112017005104A2 (pt) 2017-12-05
JP2017531039A (ja) 2017-10-19
US20180319820A1 (en) 2018-11-08
CN106852144B (zh) 2019-08-30
WO2016055791A1 (en) 2016-04-14
EP3204388A1 (en) 2017-08-16
CA2957868A1 (en) 2016-04-14
KR20170058921A (ko) 2017-05-29
US10189863B2 (en) 2019-01-29
EP3204389B1 (en) 2019-06-26
JP2017531038A (ja) 2017-10-19
US10035810B2 (en) 2018-07-31
JP6675407B2 (ja) 2020-04-01
US10273249B2 (en) 2019-04-30
US20170190718A1 (en) 2017-07-06
EA201790796A1 (ru) 2017-09-29
US10472375B2 (en) 2019-11-12
WO2016055792A1 (en) 2016-04-14
US20170305935A1 (en) 2017-10-26
SG11201701184WA (en) 2017-03-30
CN106852144A (zh) 2017-06-13
IL250823A0 (en) 2017-04-30
US20180179228A1 (en) 2018-06-28
US20170355717A1 (en) 2017-12-14
BR112017005104B1 (pt) 2022-08-23
AU2015329789A1 (en) 2017-03-09
US9732098B2 (en) 2017-08-15
EP3204389A1 (en) 2017-08-16
US20190202841A1 (en) 2019-07-04
US9926335B2 (en) 2018-03-27
EA201790796A8 (ru) 2018-10-31
AU2015329789B2 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CA2957868C (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
US10626126B2 (en) Compounds
EP3233867B1 (en) 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
EP2776416B1 (en) Pharmaceutical compounds
JP6695334B2 (ja) 呼吸器合胞体ウイルス感染症(rsv)の治療又は予防のためのスピロインドリン
Class et al. Patent application title: Novel 5, 6-dihydro-4H-benzo [b] thieno-[2, 3-d] azepine derivative
HK1242318A1 (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative
HK1242318B (en) Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908